Search

Displaying results 1701 - 1710 of 8517 in total
  1. Drug

    Trolamine salicylate

    go.drugbank.com/drugs/DB11079
    Approved

    Unlike other topical analgesics, trolamine salicylate has no distinct odor which improves patient acceptability [A32189]. … It also displays low systemic absorption upon dermal or topical administration [A32190] and has low skin irritant properties [A32191].

  2. Drug

    Isavuconazole

    go.drugbank.com/drugs/DB11633
    ApprovedInvestigational

    As isavuconazole displays low water solubility, it is found as an active ingredient of its prodrug, [DB06636]. … Resistance to isavuconazole has been associated with the mutation in the target gene CYP51 [FDA Label].

  3. Drug

    Allylestrenol

    go.drugbank.com/drugs/DB01431
    Investigational

    A synthetic steroid with progestational activity. It is widely marketed throughout Europe, including Russia and many other European countries, and is also available in Japan, Hong Kong, India, Bangladesh, Indonesia, and much of Southeast...

  4. Drug

    Nadolol

    go.drugbank.com/drugs/DB01203
    ApprovedInvestigational

    [A34177] Nadolol was granted FDA approval on 10 December 1979.[L7922] … [L7922,L7925] Nonselective beta adrenal receptor blockers may no longer be first line in the treatment of hypertension as newer generations of beta adrenal receptor blockers have higher selectivity and

  5. Drug

    Azacitidine

    go.drugbank.com/drugs/DB00928
    ApprovedInvestigational

    As an analogue of cytidine, it is able to incorporate into RNA and DNA, disrupting RNA metabolism and inhibiting protein and DNA synthesis. … [A1415] The use of oral azacitidine for the treatment of AML in patients in complete remission was approved by the FDA in September 2020.[L35335]

  6. Drug

    Loxoprofen

    go.drugbank.com/drugs/DB09212
    ApprovedInvestigational

    It is marketed under the trade name Loxonin in Brazil, Mexico and Japan by Sankyo, as Loxomac in India, and as Oxeno in Argentina. … A transdermal preparation was approved for use in Japan in January 2006.

  7. Drug

    Clavulanic acid

    go.drugbank.com/drugs/DB00766
    ApprovedInvestigationalVet approved

    [A182228]When it is combined with amoxicillin, clavulanic acid is frequently known as Augmentin, Co-Amoxiclav, or Clavulin.[L7880,L7904,L7910]

    Mixtures: AMOXICLAV BASI 500MG/125MG, AMOXICLAV BASI 500MG/125MG
  8. Drug

    ARG098

    go.drugbank.com/drugs/DB06338
    Experimental

    ARG098 (anti-Fas IgM monoclonal antibody) was studied in a Phase I clinical trial in 2007 involving patients with rheumatoid arthritis.

  9. Drug

    Caplacizumab

    go.drugbank.com/drugs/DB06081
    ApprovedInvestigational

    Caplacizumab was developed by Ablynx, a Sanofi company and FDA approved on February 6, 2019,[L5302] and approved previously by the EU in October 2018 as a combination therapy with plasma exchange and immunosuppression

  10. Drug

    Pyridoxal phosphate

    go.drugbank.com/drugs/DB00114
    ApprovedInvestigationalNutraceutical

    This is the active form of vitamin B6 serving as a coenzyme for synthesis of amino acids, neurotransmitters (serotonin, norepinephrine), sphingolipids, aminolevulinic acid.